Hospital-Based Infections

Physicians and hospitals are concerned about the problem of hospital-acquired infections, as is the US Centers for Disease Control, which has launched a campaign to prevent antimicrobial resistance in health care settings. Start-ups believe they can help, with effective and rapid tests for infectious disease and narrow spectrum antimicrobials targeted to specific pathogens. buhed ehnwhihOntros sion, acarel

Former movie mogul Samuel Goldwyn once said, "A hospital is no place to be sick," and he was right. The US Centers for Disease Control (CDC) reports that two million patients acquire infections in hospitals each year, and estimates that 90,000 of them die. There are several reasons why hospitals are such prime real estate for microbes. For one thing, many patients are vulnerable because of diseases or treatments that weaken their immune systems. Cancer patients undergoing chemotherapy, transplant patients on immunosuppression drugs, and burn patients are all susceptible to microbes in the environment. Invasive devices—catheters, central lines, ventilators—provide ports of entry for microbes, and in sick patients, common, every day bacteria lurking on skin and other surfaces can have serious consequences.

Even scarier, hospitals are breeding grounds for particularly fearsome infections: life threatening microbes like Pseudomonas aeruginosa, which causes pneumonia, and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

What Incyte Investors Expect From New CEO Bill Meury

 

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By 

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Executives On The Move: New CEO At Atalanta Therapeutics

Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.